摘要
目的:以超高效液相色谱-四极杆/静电场轨道阱质谱(UPLC-Q-Orbitrap HRMS)技术为主要手色谱段,结构定性亚硫酸氢钠甲萘醌注射液中的4个降解杂质。方法:超高效液相色谱采用Thermo Gold C_(18)色谱柱(100 mm×2.1 mm,1.9μm),以0.02 mol·L^(-1)乙酸铵溶液-甲醇(92∶8)为流动相,质谱采用HESI离子源、正负离子检测模式,碎片分析借助MsFrontier7.0软件,结构定性分析亚硫酸氢钠甲萘醌注射液中的4个降解杂质。结果:通过HPLC-PDA、UPLC-HRMS、^(1)HNMR等手段,结合有机合成制备杂质对照品、强制降解试验归属杂质来源、推测形成路径等方式,确定了亚硫酸氢钠甲萘醌的4个重要的降解杂质的分子结构,它们分别是:3-羟甲基-1,4-二-氧代-1,4-二-氢-2-萘磺酸钠(杂质1)、1-羟基-3-甲基-4-氧代-1,2,3,4-四-氢萘-1,3-二-磺酸钠(杂质2)、4-羟基3-甲基-1-氧代-1,2-二-氢-萘磺酸钠(杂质3)和1,4-二-羟基3-甲基-2-萘磺酸钠(杂质4)。结论:通过降解杂质结构定性及其互变异构、自氧化等机制研究,为亚硫酸氢钠甲萘醌注射液的工艺优化和质量控制提供了参考依据。
Objective:To confirm the structure of four degradation impurities of menadione sodium bisulfite injection using UPLC-Q-Orbitrap HRMS. Methods:UPLC was applied with a Thermo Gold C_(18) column(100 mm×2.1 mm,1.9 μm) and eluted with 0.02 mol·L^(-1) ammonium acetate solution-methanol(92∶8). MS was applied with HESI source and positive/negative ion modes. Fragment analysis was carried out by Mas Frontier7.0 software. The structures of four degradation impurities in the injection of menadione sodium bisulfite were characterized and confirmed. Results:Four degradation impurities,which were sodium 3-(hydroxymethyl)-1,4-dioxo-1,4-dihydronaphthalene-2-sulfonate(impurity 1),sodium 1-hydroxy-3-methyl-4-oxo-1,2,3,4-tetrahydronaphthalene-1,3-disulfonate(impurity 2),sodium 4-hydroxy-3-methyl-1-oxo-1,2-dihydronaphthalene-2-sulfonate(impurity 3) and sodium 1,4-dihydroxy-3-methylnaphthalene-2-sulfonate(impurity 4), were confirmed. This study used analytical methods such as HPLC-PDA,UPLC-HRMS,and ^(1)HNMR. The degradation mechanism was proposed and confirmed by organic synthesis,forced degradation etc. Conclusion:Through the structure study of the degradation impurities and the mechanism of tautomerism and auto-oxidation,this method provides a reference for the process optimization and quality control of sodium bisulfite menadione injection.
作者
程杰
李显庆
王静静
谢子立
堵伟锋
CHENG Jie;LI Xian-qing;WANG Jing-jing;XIE Zi-li;DU Wei-feng(Anhui Institute for Food and Drug Control,Hefei 230051,China;Anhui University of Chinese Medicine,Hefei 230038,China)
出处
《药物分析杂志》
CAS
CSCD
北大核心
2021年第9期1538-1549,共12页
Chinese Journal of Pharmaceutical Analysis
基金
2017年度药典委标准提高项目